Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Sep 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Zero Revenue ⢠Persistent Cash Burn RAPP's strong cash-rich balance sheet is offset by zero revenue, heavy losses, persistent cash burn, and reliance on equity financing, making it a high-risk valuation at 4.8x book value.
Price Behavior
Key Price Behavior Insights: ⢠Failed breakout ⢠Momentum reversal ⢠Key support Support Level: $45.50â$46.00 Resistance Level: $48.50â$49.30 RAPP weakened over the last month after failing to hold $52.50, with $45.50â$46.00 support and a recovery above $49.30 needed to improve momentum.
Sentiment & News
Key News Insights: ⢠52-Week High ⢠Institutional Buying ⢠Phase 3 Runway Rapport Therapeutics hit a 52-week high amid rising institutional buying and continued RAP-219 clinical/investor outreach, supported by cash runway into 2029 but tempered by future funding and regulatory risks.
AI Summary
RAPP is a well-funded but highly valuation-sensitive clinical catalyst bet: October 2026 bipolar-mania data is the key near-term inflection, while its $2.04B valuation leaves substantial downside if RAP-219 lacks compelling efficacy or tolerability; maintain a watchful stance until data de-risks the program.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |